Benzinga | Oct 14, 2021 07:39AM EDT

SVB Leerink Initiates Coverage On C4 Therapeutics with Outperform Rating, Announces Price Target of $67

SVB Leerink analyst Andrew Berens initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Outperform rating and announces Price Target of $67.